Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a safer drug replace magnesium for seizure prevention in pregnancy?

NCT ID NCT07220902

Prevention Sponsor: Nebraska Methodist Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether levetiracetam, a seizure medication, works as well as magnesium sulfate to prevent seizures in pregnant people with severe preeclampsia. About 1,240 participants at 32 weeks or more will be randomly assigned to one of the two drugs. The goal is to see if levetiracetam can prevent seizures with fewer side effects for both mother and baby.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jul 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant or postpartum women aged 19 years or older * Diagnosed with preeclampsia with severe features, superimposed preeclampsia or HELLP syndrome * At risk for eclampsia and eligible for seizure prophylaxis * Less than 2 hours exposure to magnesium sulfate or greater than 48 hours since last dose. * Admitted or plan to proceed with delivery Exclusion Criteria: * \<32 weeks estimated gestational age * History of epilepsy or seizure disorders unrelated to pregnancy * Allergy or contraindication to Levetiracetam or Magnesium Sulfate * Severe renal impairment (Oliguria \<120ml in 4 hours) * Plan for neonatal comfort care

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eclampsia preeclampsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eclampsia HELLP syndrome preeclampsia severe pre-eclampsia visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eclampsia preeclampsia Severe preeclampsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Methodist Women's Hospital

    Omaha, Nebraska, 68022, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.